$RNST

RENASANT CORP (RNST): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

RENASANT CORP (RNST) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Contacts: For Media: For Financials: John S. Oxford James C. Mabry IV Senior Vice President Executive Vice President Chief Marketing Officer Chief Financial Officer (662) 680-1219 (662) 680-1281 joxford@renasant.com jim.mabry@renasant.com Renasant Announces Chief Fin

Original reporting
Published Aug 25, 2026, 8:49 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 25, 2026, 8:57 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$RNST
Neutral
high confidence
Mentioned
$RNST
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$RNSTNeutralLow
01

Why it matters

The announcement provides clarity on succession planning and may reassure investors about governance continuity.

02

Market read

Executive changes are material corporate actions but typically have modest immediate market impact.

03

What to watch

Potential hidden cost synergies or cultural fit issues with the new CFO's background at KBW.

Relevance 6/10Novelty 6/10Timing: effective Oct 5, 2026; CFO start Jan 1, 2027

Background

The filing is an SEC Form 8‑K reporting a leadership transition at Renasant Corp, a $27 bn asset regional bank.

Company-level read

Ticker impact

$RNSTNeutralHigh confidence
Context

Renasant Corp announced the appointment of Catherine Mealor as CFO effective Jan 1, 2027 and the retirement of Jim Mabry.

Expected impact

Limited short-term impact; potential modest upside if market views new CFO favorably.

Evidence & confidence

CFO changes are material but typically do not cause large price moves; the market will assess Mealor's experience in banking.

Market effects

May signal stability in the regional banking sector as Renasant continues its growth trajectory.

Limited to the Southeast U.S. banking market where Renasant operates.

Minimal; primarily a domestic banking news item.

Counterpoint

The CFO change could be a distraction and may not improve performance if integration challenges arise.

Key entities

  • Catherine Mealor

    Incoming Executive Vice President and Chief Financial Officer.

  • Jim Mabry

    Outgoing CFO, transitioning to retirement and board nomination.

Related articles

$RNSTMed

Renasant Q2 Earnings Call Highlights

Renasant (NYSE:RNST) management said it expects core margins to stay generally stable in the second half, citing loan maturities of about $1.25B over 12 months at ~4.95% and $50M to $60M monthly securities roll-offs into upper-4% to near-5% yields. The company is not adjusting its outlook for a Fed rate change. Q2 net interest income was $227.7M, non-interest income $51.2M, pre-provision net revenue $112.4M, and it recorded a $3.8M credit-loss provision.

$RNSTMed

RENASANT CORP (RNST): Results of Operations and Financial Condition

RENASANT CORP (RNST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991_rnstx2q2026earn.htm EX-99.1 Document Contacts: For Media: For Financials: John S. Oxford James C. Mabry IV Senior Vice President Executive Vice President Chief Marketing Officer Chief Financial Officer (662) 680-1219 (662) 680-1281 RENASANT CORPORATION ANNOUN

$ACVAMed

Robust Results and Share Repurchase Authorization Boosted ACV Auctions (ACVA)

Meridian Hedged Equity Fund highlighted ACV Auctions (ACVA) in its Q2 2026 investor letter, noting its record Q1 results, $100M share repurchase plan, and AI-driven solutions. ACVA's stock declined 10.19% over the past month and 43.27% over the past year, with a market cap of $1.14B. The fund holds ACVA, citing its market share gains and strong fundamentals.

$NTLAMedAI 9/10

Intellia Secures Up To $400 Mln Non-Dilutive Debt Facility From OrbiMed

Intellia Therapeutics (NTLA) secured a $400 million debt facility from OrbiMed, with $75 million funded at closing and $225 million tied to milestones for lonvo-z, a CRISPR gene-editing therapy. The facility provides financial flexibility for lonvo-z's development and potential U.S. launch for hereditary angioedema (HAE). NTLA shares are up 0.63% at $12.76.